Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Biocad clinical trials
The registry lists 94 studies whose lead sponsor is Biocad. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 1, 2026.
Keep track of what changes. Save the Biocad studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Biocad.
- Biocad94 studiesSame company
Something wrong?
Related but not counted here: SPH-BIOCAD (HK) Limited (affiliate).
Studies
Recruiting first, then most recently updated. Showing 50 of 94. Browse all 94 →
- A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)RecruitingNCT07742215Phase 3
- A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple SclerosisRecruitingNCT07321093Phase 3
- An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia BRecruitingNCT06700096Phase 3
- Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative ColitisRecruitingNCT07080034Phase 2
- Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's DiseaseRecruitingNCT07078994Phase 2
- Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus ErythematosusRecruitingNCT07136389Phase 1
- BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast CancerRecruitingNCT07108309Phase 2
- Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)RecruitingNCT06120582Phase 1/2
- An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple MyelomaRecruitingNCT06668792Phase 2
- Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy SubjectsRecruitingNCT06715540Phase 1
- A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple MyelomaRecruitingNCT06296121Phase 3
- Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)RecruitingNCT05747261Phase 1/2
- Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisActive, not recruitingNCT07119372Phase 3
- A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy SubjectsCompletedNCT07181694Phase 1
- Clinical Study of Divozilimab in Patients With Systemic SclerodermaActive, not recruitingNCT05726630Phase 3
- Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT06640517Phase 3
- Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast CancerActive, not recruitingNCT05802225Phase 3
- International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing SpondylitisCompletedNCT03447704Phase 3
- Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06640530Phase 3
- A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06112808Phase 1
- Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic ArthritisCompletedNCT03598751Phase 3
- A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaActive, not recruitingNCT05751928Phase 3
- An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURNCompletedNCT06987864Phase 3
- An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCADCompletedNCT06987851Phase 3
- A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia AActive, not recruitingNCT06185335Phase 1/2
- A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaActive, not recruitingNCT05732805Phase 3
- Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple SclerosisCompletedNCT04056897Phase 2
- An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple SclerosisCompletedNCT05385744Phase 3
- Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)Active, not recruitingNCT05730699Phase 3
- Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)Active, not recruitingNCT06333210Phase 3
- Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy VolunteersCompletedNCT05407779Phase 1
- A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung CancerCompletedNCT01763645Phase 3
- A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy SubjectsCompletedNCT05974969Phase 1
- Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced MelanomaActive, not recruitingNCT05986331Phase 3
- Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced MalignanciesActive, not recruitingNCT05739006Phase 1
- Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial SpondyloarthritisActive, not recruitingNCT05445076Phase 2
- A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid ArthritisActive, not recruitingNCT05800327Phase 3
- Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05783882Phase 3
- Phase 1 Study of BCD-245 in Subjects With NeuroblastomaStatus unknownNCT05782959Phase 1
- A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy VolunteersStatus unknownNCT05738993Phase 1
- Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple SclerosisCompletedNCT02727907Phase 2/3
- Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT03913923Phase 2
- Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)TerminatedNCT05037188Phase 1/2
- An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT03390101Phase 3
- Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid ArthritisCompletedNCT04227366Phase 3
- A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19CompletedNCT04397562Phase 3
- The BCD-089 (aIL6R) in Patients With Active Rheumatoid ArthritisCompletedNCT03455842Phase 2
- Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy VolunteersCompletedNCT02395055Phase 1
- Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing SpondylitisCompletedNCT02763111Phase 2
- Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT02753088Phase 3